DATASET FOR FACTOR V LEIDEN IN SUBJECTS WITH PREECLAMPSIA

Published: 6 Nov 2019 | Version 3 | DOI: 10.17632/zvbbtby75p.3
Contributor(s):
  • Grace Ababio,
    Agricultural and Biological Sciences
    University of Ghana School of Medicine and Dentistry, Medical Biochemistry, Korle-Bu, Accra
    Conceptualization, Experimental, Data Analysis, write-up, resources, supervision, funding acquisition
  • Kwame Adu-Bonsaffoh ,
    Medicine and Dentistry
    University of Ghana School of Medicine and Dentistry, Obstetric and Gynecology, Korle-Bu Accra
    Conceptualization, Methodology, Analysis, Proofreading of write-up
  • Emmanuel Abindao,
    Emmanuel Abindao
    University of Ghana School of Medicine and Dentistry, Physiology Department, Korle-Bu, Accra
    Investigation, Experimental, Analysis
  • Grace Narh,
    Grace Narh
    University of Ghana, Biochemistry Department, Legon, Accra
    Experimental, Data Analysis
  • Diana Tetteh,
    Diana Tetteh
    National Diabetes Research Center, Korle-Bu, Accra
    Investigation, Experimental
  • Felix Botchway,
    Medicine and Dentistry
    Korle-Bu Teaching Hospital, Child Health, Accra
    Investigation, Experimental
  • Diana Morvey,
    Diana Morvey
    Clinical Documentation Specialist, Culver State, California
    Experimental, Investigation
  • Jonathan Neequaye,
    Biochemistry, Genetics and Molecular Biology
    KNUST, Kumasi, Ghana
    Investigation, Experimental
  • Isaac Quaye
    Isaac Quaye
    Regent University of Science and Technology, Allied Health, Accra
    Conceptualization, Resources, Data Analysis, Proofreading

Description of this data

In Ghana, there is limited information regarding factor V Leiden polymorphism on the pathogenesis of preeclampsia (PE) and its associated outcomes; hence, the focus of the current study. Eighty-one (81) consented subjects were recruited after ethical clearance was obtained and structured questionnaire administered to them. Routine blood chemistry and characterization of Factor V Leiden were obtained for subjects. We found FVL mutation much more in PE and hypertensive patients. FVL exon 10 were 0.67 and 0.33 for G and A alleles respectively. There was an absence of FVL mutation in exon 8 in the current study. Increased white blood cells, increased uric acid and a three – fold increment of AST / ALT ratio were observed among PE cases when stratified by FVL exons (exon 8 and 10). This study was the first to report baseline FVL genotypic and allelic frequencies as well as relating clinical variables with it.

Experiment data files

Latest version

Statistics

Views: 21
Downloads: 0

Previous versions

  • Version 3

    2019-11-06

    Published: 2019-11-06

    DOI: 10.17632/zvbbtby75p.3

    Cite this dataset

    Ababio, Grace; Adu-Bonsaffoh , Kwame; Abindao, Emmanuel; Narh, Grace; Tetteh, Diana; Botchway, Felix; Morvey, Diana; Neequaye, Jonathan; Quaye, Isaac (2019), “DATASET FOR FACTOR V LEIDEN IN SUBJECTS WITH PREECLAMPSIA”, Mendeley Data, v3 http://dx.doi.org/10.17632/zvbbtby75p.3

  • Version 2

    2019-11-06

  • Version 1

    2019-11-06

Compare to version

Categories

Coagulation Factor V

Licence

CC BY 4.0 Learn more

The files associated with this dataset are licensed under a Creative Commons Attribution 4.0 International licence.

What does this mean?
You can share, copy and modify this dataset so long as you give appropriate credit, provide a link to the CC BY license, and indicate if changes were made, but you may not do so in a way that suggests the rights holder has endorsed you or your use of the dataset. Note that further permission may be required for any content within the dataset that is identified as belonging to a third party.

Report